Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

McClellan’s “Smart Regulation”: More Early Testing And Phase IV Studies

Executive Summary

Increased emphasis on early stage testing and Phase IV studies could result in lower drug development costs, FDA Commissioner Mark McClellan said Dec. 11

You may also be interested in...



FDA Patient Safety Strategy Would Shift AE Monitoring To Automated Systems

FDA plans to unveil a broad patient safety strategy over the next few months that will explain how the agency plans to move away from reliance on voluntary reporting to use of automated systems to collect adverse event and medical errors data

FDA Patient Safety Strategy Would Shift AE Monitoring To Automated Systems

FDA plans to unveil a broad patient safety strategy over the next few months that will explain how the agency plans to move away from reliance on voluntary reporting to use of automated systems to collect adverse event and medical errors data

Commissioner McClellan Visits Mass Bio: Phase IV, Orphan Drugs On Agenda

Phase IV commitments should be discussed earlier in the review process to improve the cost-effectiveness of drug development, the Massachusetts Biotechnology Council told FDA Commissioner McClellan

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel